Table 3.
Study (ref) | Country | Period | Age (years) | Age at HZ-related death | Mortality incidence/100 000 (95% CI) | Case fatality rate (%) | Hospital fatality rate (%) | Number |
---|---|---|---|---|---|---|---|---|
Bilcke 2011 [21] | Belgium | 1990-2007 | 60-70 | 0.06 | ||||
70+ | 0.63 | |||||||
Gonzalez Chiappe 2010 [27] | France | 2000-2007 | Overall | 96.8% (1360; 170/year) in those aged ≥65 years | 0.286 (0.244-0.328) | 0.075 | 2.012 | 1 405 (176 ± 13/year) |
≥65 | 4.36 ± 0.20 | |||||||
45-54 | 0.031 (0–0.069) | 0.007 | ||||||
55-64 | 0.072 (0.009-0.135) | 0.012 | ||||||
65-74 | 0.236 (0.102-0.370) | 0.027 | ||||||
75-84 | 1.25 (0.90-1.60) | 0.127 | ||||||
85-94 | 7.24 (5.66-8.82) | 0.672 | ||||||
≥95 | 19.48 (11.50-27.47) | 1.356 | HFR: Malignancies: 4.236 (449/10 599) HIV/AIDS: 0.357 (26/7 277) | |||||
Diabetes: 1.654 (94/5 682) | ||||||||
Blood dyscrasias: 3.907 (82/2 099) | ||||||||
RA: 1.759 (38/2 160) | ||||||||
Malnutrition: 6.196 (64/1 033) | ||||||||
Organ transplant: 0.049 (1/2 023) | ||||||||
Ultsch 2011 [30] | Germany | 2007-2008 | 50-54 | 73% (n = 48) deaths in ≥80 years | 0.02 (0.00-0.10) | 0.003 | 1 | |
55-59 | 0.00 NA | 0 | 0 | |||||
60-64 | 0.02 (0.00-0.13) | 0.003 | 1 | |||||
65-69 | 0.06 (0.01-0.17) | 0.005 | 3 | |||||
70-74 | 0.11 (0.04-0.27) | 0.010 | 5 | |||||
75-79 | 0.30 (0.14-0.57) | 0.025 | 9 | |||||
80-84 | 0.54 (0.28-0.94) | 0.043 | 12 | |||||
85-89 | 1.20 (0.67-1.98) | 0.096 | 15 | |||||
≥90 | 3.86 (2.36-5.96) | 0.293 | 20 | |||||
Overall | 0.21 (0.16-0.26) | 0.022 | 66 | |||||
van Lier 2010 [31] | Netherlands | 2000-2007 | ≥60 | 92% deaths occurred in ≥ 75 years | 0.59 (estimated with pop ≥60 from Eurostat) | Mean 18 deaths/year (range 13–26) | ||
de Melker 2006 [23] | Netherlands | 1996-2002 | ≥75 | 97% occurred in ≥60 years | 1.92 (estimated with pop ≥75 from Eurostat) | Mean 18 deaths/year (range 13 to 26) | ||
Mesquita 2013 [28] | Portugal | 2000-2010 | 50-59 | 76.8 years (SD = 13.6) | 1.0 | 17 (total) | ||
60-69 | 0.4 | |||||||
70-79 | 0.8 | |||||||
80-89 | 2.9 | |||||||
90-99 | 3.8 | |||||||
Perez-Sola 2011 [29] | Spain | 2000-2006 | 0 | |||||
Gil 2009 [24] | Spain | 1998-2004 | 50-59 | 0.3 | 3.8 | 156/year (mean) | ||
60-69 | 0.6 | 3.7 | ||||||
70-79 | 1.5 | 4.5 | ||||||
≥80 | 3.9 | 7.1 | ||||||
Gil-Prieto 2011 [26] | Spain | 1998-2004 | 50-59 | 3.0*/1.1 | ||||
60-69 | 2.7*/1.7 | |||||||
≥70 | 5.3*/2.7 | |||||||
50-59 | No comorbidity: 1.1 | |||||||
Comorbidity: 3.0 | ||||||||
Diabetes: 3.0 | ||||||||
COPD: 4.2 | ||||||||
CVD: 3.7 | ||||||||
60-69 | No comorbidity: 1.7 | |||||||
Comorbidity: 2.7 | ||||||||
Diabetes: 1.9 | ||||||||
COPD: 2.7 | ||||||||
CVD: 3.4 | ||||||||
≥70 | No comorbidity: 2.7 | |||||||
Comorbidity: 5.3 | ||||||||
Diabetes: 5.0 | ||||||||
COPD: 5.0 | ||||||||
CVD: 5.9 | ||||||||
Gil-Prieto 2012 [25] | Spain | 1997-2008 | First diagnosis | |||||
≥50§ | 2.51§ (1.42-3.61)/ | 20 | ||||||
≥50# | 1.62# (0.67-2.5) | 11 | ||||||
50-59 | ||||||||
60-69 | 0/0 | 0§/0# | ||||||
≥70 | 1.16§ (0–0.76)/0# | 2§/0# | ||||||
3.61§ (1.97-6.25)/ | 18§/11# | |||||||
2.48# (1.03-3.93) | ||||||||
All ages | 22§/11# | |||||||
1.89§ (1.1-1.27)/ | ||||||||
1.22# (1.9-5.0) | ||||||||
Any diagnosis: | ||||||||
≥50 | 117§/70# | |||||||
50-59 | 4§/1# | |||||||
60-69 | 16§/3# | |||||||
≥70 | 97§/66# | |||||||
Brisson 2003 [22] | England & Wales | 1991-2000 | 45-64$ | 0.014 | 0.002 | 0.612 | 2$ | |
≥65$ | 0.566 | 0.061 | 3.190 | 47 | ||||
all ages$$ | 0.094 | 0.031 | 2.722) | 49 | ||||
Edmunds 2001 [2] | England & Wales | 1995-1999 | ≥60 | 2.0 – 4.0 | ||||
50-54 | 0.009 | |||||||
55-59 | 0.009 | |||||||
60-64 | 0.027 | |||||||
65-69 | 0.027 | |||||||
70-74 | 0.035 | |||||||
75-79 | 0.092 | |||||||
80-84 | 0.487 | |||||||
≥85 | 2.018 |
*in those with diabetes, COPD and cardiovascular; § all; #immuno-competent; $data from national statistics; $$ HES data base.